Literature DB >> 32538846

Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease.

Mario Hernandes-Alejandro1, Sarita Montaño2, Charles R Harrington3, Claude M Wischik3, Andrés Salas-Casas4, Pedro Cortes-Reynosa5, Eduardo Pérez Salazar5, Javier Cazares-Apatiga6, Ricardo Apatiga-Perez7,8, Miguel Ángel Ontiveros Torres9, George Perry10, Mar Pacheco-Herrero11, José Luna-Muñoz8.   

Abstract

BACKGROUND: Neurofibrillary tangles (NFTs) and amyloid plaques are the neuropathological hallmarks in brains with Alzheimer's disease (AD). Post-translational modifications of tau, such as phosphorylation and truncation, have been proposed as initiators in the assembly of the abnormal paired helical filaments that constitute the NFTs. Neurons and NFTs are sites of matrix metalloproteinases (MMPs).
OBJECTIVE: The aim of this study was to analyze the relationship of MMP-9 and tau protein in brain samples with AD.
METHODS: This study was performed on brain tissue samples from patients with early, moderate, and late AD. MMPs and tau levels were analyzed by western blot and gelatin-substrate zymography. Immunofluorescence techniques and confocal microscopy were used to analyze the presence of both proteins in NFTs. Further, molecular dynamics simulations (MDS) and protein-protein docking were conducted to predict interaction between MMP-9 and tau protein.
RESULTS: MMP-9 expression was greatest in moderate and late AD, whereas MMP-2 expression was only increased in late-stage AD. Interestingly, confocal microscopy revealed NFTs in which there was co-localization of MMP-9 and tau protein. MDS and protein-protein docking predictions indicate that a high-affinity complex can be formed between MMP-9 and full-length tau protein.
CONCLUSION: These observations provide preliminary evidence of an interaction between these two proteins. Post-translational modifications of tau protein, such as C-terminal truncation or phosphorylation of amino acid residues in the MMP-9 recognition site and conformational changes in the protein, such as folding of the N-terminal sequence over the three-repeat domain, could preclude the interaction between MMP-9 and tau protein during stages of NFT development.

Entities:  

Keywords:  Alzheimer’s disease; matrix metalloproteinase-9; molecular dynamics zzm321990simulation; protein-protein docking; tau protein

Mesh:

Substances:

Year:  2020        PMID: 32538846     DOI: 10.3233/JAD-200146

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

Review 1.  The Role of Extracellular Matrix Components in the Spreading of Pathological Protein Aggregates.

Authors:  Edoardo Moretto; Skye Stuart; Sunaina Surana; Jose Norberto S Vargas; Giampietro Schiavo
Journal:  Front Cell Neurosci       Date:  2022-04-29       Impact factor: 6.147

2.  MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Charis Ringland; Jonas Elias Schweig; Maxwell Eisenbaum; Daniel Paris; Ghania Ait-Ghezala; Michael Mullan; Fiona Crawford; Laila Abdullah; Corbin Bachmeier
Journal:  BMC Neurosci       Date:  2021-05-25       Impact factor: 3.288

3.  In Silico Analysis of Metabolites from Peruvian Native Plants as Potential Therapeutics against Alzheimer's Disease.

Authors:  Luis Daniel Goyzueta-Mamani; Haruna Luz Barazorda-Ccahuana; Miguel Angel Chávez-Fumagalli; Karla Lucia F Alvarez; Jorge Alberto Aguilar-Pineda; Karin Jannet Vera-Lopez; Christian Lacks Lino Cardenas
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

4.  Tau Protein Modulates Perineuronal Extracellular Matrix Expression in the TauP301L-acan Mouse Model.

Authors:  Sophie Schmidt; Max Holzer; Thomas Arendt; Mandy Sonntag; Markus Morawski
Journal:  Biomolecules       Date:  2022-03-26

Review 5.  The Role of Extracellular Matrix in Human Neurodegenerative Diseases.

Authors:  Panka Pintér; Alán Alpár
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

6.  Little genomic support for Cyclophilin A-matrix metalloproteinase-9 pathway as a therapeutic target for cognitive impairment in APOE4 carriers.

Authors:  Emma L Anderson; Dylan M Williams; Venexia M Walker; Neil M Davies
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.